Abstract
Tyrosine kinase inhibitors with activity against BCR-ABL form the cornerstone of CML therapy, and are particularly effective in those with chronic-phase disease. Because some patients exhibit primary resistance or secondary failure to TKI therapy, it is recommended that continued monitoring of disease burden be performed. In this article, we review methods of detecting the Philadelphia chromosome and BCR-ABL transcript, and discuss the correlation of response with patient outcomes. Expert guidelines that incorporate definitions and milestones of response are referenced to aid in clinical decision-making.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
